靶向线粒体质量控制防治椎间盘退变的研究进展

Research advances in prevention and treatment of intervertebral disc degeneration by targeting mitochondrial quality control

椎间盘退变(IDD)是一种临床常见的肌肉骨骼系统退行性疾病,可增加下腰痛发病的风险,严重降低患者生活质量和工作效率,给社会带来较大的经济负担。线粒体作为真核细胞的“发电站”,参与许多关键的生物过程,其功能异常可诱发细胞功能障碍,导致一系列退行性疾病的发生。近年来的研究发现,以线粒体氧化应激、动力学、自噬和生物发生等异常为特征的线粒体质量控制(MQC)失衡在IDD中发挥重要作用。该研究综述MQC在IDD中的作用进展,总结靶向MQC治疗IDD的中药单体和小分子化合物,以期为椎间盘退变的新型治疗策略研究提供借鉴及思路。

Intervertebral disc degeneration(IDD) is a common clinical degenerative disease of the musculoskeletal system, which increases the risk of lower back pain, severely reduces patients′ quality of life and work efficiency, and imposes a large economic burden on society. Mitochondria, as the "power stations" of eukaryotic cells, are involved in many key biological processes, and their abnormal function can induce cellular dysfunction and lead to the development of a series of degenerative diseases. Recent studies have revealed that mitochondrial quality control(MQC) imbalance, characterized by abnormalities in mitochondrial oxidative stress, kinetics, mitophagy and biogenesis, plays an important role in IDD. The research reviewed the progress of the role of MQC in IDD and summarized traditional Chinese medicine monomers and small molecule compounds targeting MQC for the treatment of IDD, with the aim of providing reference and new ideas for studying novel therapeutic strategies for IDD.